$10.150
+0.020 (+0.20%)收盘时
ITOS 资讯
ITOS 事件
Vor Bio Names Osovsky as General Counsel
Vor Bio (VOR) announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. Dr. Osovsky joins Vor Bio from iTeos Therapeutics (ITOS), where she served as Executive Vice President, Head of Legal & Corporate Secretary.
Vor Bio appoints Cumbo, Detheux to board of directors
Vor Bio (VOR) announced the appointment of Alexander Cumbo and Michel Detheux, Ph.D., to its Board of Directors, effective July 16, 2025. Alexander Cumbo currently serves as President and Chief Executive Officer of Solid Biosciences (SLDB). Michel Detheux, Ph.D., is President and Chief Executive Officer of iTeos Therapeutics (ITOS)
iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR
iTeos Therapeutics entered into a definitive merger agreement whereby Concentra Biosciences will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share, plus one non-transferable contingent value right, which represents the right to receive: 100% of the closing net cash of iTeos in excess of $475M; and 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing. Following a strategic review process conducted with the assistance of iTeos' management and legal and financial advisors, the iTeos board of directors has unanimously determined that the acquisition by Concentra is in the best interests of all iTeos stockholders and has approved the merger agreement and related transactions. Pursuant and subject to the terms of the merger agreement, Concentra will commence a tender offer by August 1, 2025, to acquire all outstanding shares of iTeos common stock for the Offer Consideration. The closing of the offer is subject to certain conditions, including the tender of a number of shares of iTeos common stock that, together with shares of iTeos Common Stock owned by Concentra or its affiliates, represents at least a majority of the total number of outstanding shares, the availability of at least $475M of cash at closing, and other customary closing conditions. Immediately following the closing of the offer, iTeos will be acquired by Concentra, and all remaining shares not tendered in the offer, other than shares owned directly or indirectly by iTeos, Concentra or a subsidiary thereof, or a holder who properly demands appraisal, will be converted into the right to receive the same Offer Consideration per share of iTeos Common Stock as is provided in the offer. Subject to the satisfaction or waiver of customary closing conditions, the transaction is expected to close in the third quarter of 2025.
iTeos Therapeutics announces intention to wind down operations
iTeos Therapeutics announced the intention to wind down its operations as part of a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Following a thorough assessment of the Company's development pipeline, business prospects, and financial position, the Company's Board of Directors intends to wind down clinical and operational activities and focus on leveraging the Company's cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the Company's intellectual property and assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1.
iTeos Therapeutics initiates targeted review of strategic alternatives
The Company is taking immediate steps to preserve capital and has initiated a targeted process to identify opportunities that preserve and maximize shareholder value. iTeos has engaged TD Cowen to advise on this process. "We are truly disappointed by the results from GALAXIES Lung-201," said Michel Detheux, Ph.D., president and chief executive officer of iTeos. "Following the analysis of the TIGIT data generated to-date with GSK, we have made the mutual decision to discontinue development of all ongoing TIGIT studies. We are grateful to all patients, caregivers, and investigators involved in the GALAXIES studies and believe it is important to share these data with the scientific community at an upcoming medical meeting in order to advance our collective understanding of immuno-oncology and TIGIT. Since founding this company over a decade ago, I could not be prouder of the team we have built, the quality of science produced, and our collective commitment to improving the lives of cancer patients in need. However, given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets. With a strong balance sheet and a commitment to disciplined execution, we are well positioned to pursue opportunities that maximize shareholder value," continued Dr. Detheux.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。